Breast Cancer

Atezolizumab/Nab-Paclitaxel of No Benefit in PD-L1–Negative Triple-Negative Breast Cancer

May 2019 Vol 10, No 5

Atezolizumab plus nab-paclitaxel was the first immunotherapy combination to improve disease-free survival (DFS) and overall survival (OS) in women with metastatic triple-negative breast cancer (TNBC) versus placebo plus nab-paclitaxel in the overall analysis of the IMpassion130 trial. Survival improvement was even more robust in the PD-L1–positive cohort.

Adjuvant Chemotherapy May Not Be Needed for Localized Breast Cancer If pCR Is Attained on Neoadjuvant Chemotherapy

May 2019 Vol 10, No 5

Reaching pathologic complete response (pCR) after neoadjuvant chemotherapy correlates with significantly improved event-free survival (EFS) and overall survival (OS) in patients with localized breast cancer, according to a large comprehensive meta-analysis presented at the 2018 San Antonio Breast Cancer Symposium.

FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer

Yvette Florio Lane

Web Exclusives

On April 4, 2019, the US Food and Drug Administration (FDA) expanded the indication of palbociclib (Ibrance; Pfizer), a kinase inhibitor, in combination with specific endocrine therapies for men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This is the first hormonal-based therapy to be approved for men.

Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness

Yvette Florio Lane

Web Exclusives

On March 27, 2019, the US Food and Drug Administration (FDA) issued an alert from its Office of Women’s Health announcing that, after more than 20 years of regulatory oversight, the agency is proposing amendments to the existing policy governing mammography services.

Exercise During Chemotherapy Improves Cardiovascular Function in Women with Breast Cancer

March 2019 Vol 10, No 3

A 12-month supervised exercise program improved cardiovascular function in women undergoing adjuvant chemotherapy for breast cancer—including anthracyclines and taxanes—while cardiovascular function decreased among controls who did not exercise according to the program guidelines.

Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer

2018 Third Annual Oncology Guide to New FDA Approvals

On March 13, 2017, the US Food and Drug Administration (FDA) approved ribociclib (Kisqali; Novartis), an oral CDK4/CDK6 inhibitor, in combination with letrozole for the treatment of postmenopausal women with HR-positive, HER2-negative advanced breast cancer.

Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Loretta Fala

2018 Third Annual Oncology Guide to New FDA Approvals

Efficacy of the Breast Cancer Navigator Role in Reducing Distress in Newly Diagnosed Breast Cancer Patients: A Pilot Study

Patricia Johnson, BS, RN, OCN, CBCN

May 2018 Vol 9, No 5

The authors present their findings from a study testing the effects of an early intervention by the Breast Cancer Navigator on distress.

Updated NCCN Breast Cancer Guidelines Add Options for HER2-Positive Disease, Emphasize CDK4/6 Inhibition in Hormone-Sensitive Cancer

May 2018 Vol 9, No 5

Updated NCCN Breast Cancer Guidelines

Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer

May 2018 Vol 9, No 5